Search

Recent studies have revealed the potential of 2D moiré superlattices as a condensed matter quantum simulator. The realization of different lattice model Hamiltonians in moiré superlattices has become the focus of researches. Here, it shows that, compared to bilayer moiré superlattices where there is only one interface, the interference between moiré patterns at different interfaces in 2D multilayer structures allows the physical realization of more complicated lattice models. The concept is demonstrated by trilayer moiré superlattices (TMSLs) of MoS2, where it finds that isolated flat moiré bands appear near the valence band edge, and they can be described by the honeycomb lattice ionic Hubbard model. More importantly, the hopping strength, the on‐site Coulomb repulsion, and the staggered potential in the TMSLs are highly tunable through the control of the twist angle, the dielectric environment, and the perpendicular electric field. It is possible to achieve various transitions between distinct quantum phases in the TMSLs, spanning from weak to strong correlation regimes. Therefore, the proposed TMSLs can serve as a good platform to study the strong correlation physics in the honeycomb lattice ionic Hubbard model. [ABSTRACT FROM AUTHOR]

All-trans retinoic acid (ATRA) is one of essentially active metabolite of vitamin A, and plays an important role in diverse physiological processes, such as cellular growth and function. Renal interstitial fibrosis (RIF) is a common pathological characteristic of chronic renal disease causing end-stage renal disease currently lacking effective treatment. Low level of Angiopoietins-1 (Angpt-1) is associated with extracellular matrix accumulation and fibrosis diseases. This study was performed to assess the association of ATRA with Angpt-1 in RIF disease. Rats were divided into three groups: group of sham (SHO group), group of unilateral ureteral obstruction group (UUO group), UUO mice administrated daily at the dose of ATRA (ATRA group). Masson-staining was used to detect the histologic lesion. Immunohistochemistry and Western-blot were applied to determine the targeted proteins. RIF score was significantly increased in UUO rats when compared with that of SHO group, and the fibrosis score was notably reduced in ATRA group. Transforming growth factor-β1 (TGF-β1), collagen IV (Col-IV) and fibronectin (FN) expressions in UUO group were significantly up-regulated, whereas Angpt-1 expression was significantly down-regulated compared with the SHO group. ATRA treatment reduced TGF-β1, Col-IV and FN expressions and improved Angpt-1 expression compared with the UUO group. The protein expression of Angpt-1 in kidney tissue of UUO group was negatively correlated with RIF index and protein expressions of Col-IV, FN and TGF-β1. In conclusion, low expression of Angpt-1 was associated with the RIF disease and ATRA treatment can increase the Angpt-1 and alleviate the RIF lesion in UUO rats. [ABSTRACT FROM AUTHOR]

Mesenchymal stem cells (MSCs), discovered and isolated from the bone marrow in the 1960s and with self-renewal capacity and multilineage differentiation potential, have valuable immunomodulatory abilities. Acute kidney injury (AKI) refers to rapid renal failure, which exhibits as quickly progressive decreasing excretion in few hours or days. This study was performed to assess the efficacy of MSCs in the treatment of AKI induced by ischemia-reperfusion using a meta-analysis method. A literature search using corresponding terms was performed in the following databases: Embase, Cochrane Library, PubMed, and ISI Web of Science databases up to Dec 31, 2019. Data for outcomes were identified, and the efficacy of MSCs for AKI was assessed using Cochrane Review Manager Version 5.3. Nineteen studies were eligible and recruited for this meta-analysis. MSC treatment can reduce the Scr levels at 1 day, 2 days, 3 days, 5 days, and >7 days (1 day: WMD = − 0.56 , 95% CI: -0.78, -0.34, P < 0.00001 ; 2 days: WMD = − 0.58 , 95% CI: -0.89, -0.28, P = 0.0002 ; 3 days: WMD = − 0.65 , 95% CI: -0.84, -0.45, P < 0.00001 ; 5 days: WMD = − 0.35 , 95% CI: -0.54, -0.16, P = 0.0003 ; and >7 days: WMD = − 0.22 , 95% CI: -0.36, -0.08, P = 0.002) and can reduce the levels of BUN at 1 day, 2 days, 3 days, and 5 days (1 day: WMD = − 11.72 , 95% CI: -18.80, -4.64, P = 0.001 ; 2 days: WMD = − 33.60 , 95% CI: -40.15, -27.05, P < 0.00001 ; 3 days: WMD = − 21.14 , 95% CI: -26.15, -16.14, P < 0.00001 ; and 5 days: WMD = − 8.88 , 95% CI: -11.06, -6.69, P < 0.00001), and it also can reduce the levels of proteinuria at 3 days and >7 days and alleviate the renal damage in animal models of AKI. In conclusion, MSCs might be a promising therapeutic agent for AKI induced by ischemia-reperfusion. [ABSTRACT FROM AUTHOR]

Kidney stones constitute a disease of the urinary system of high incidence that has only a few available stone dissolving drugs as treatment options. The mechanism of calcium oxalate stone formation is still largely unclear. Various aspects and theories for initiation and formation of the renal stones have been suggested, and the complex multistep formation process of the kidney stones includes supersaturation, nucleation, growth and aggregation of a crystal, and crystal retention in cells after adhesion. During the initial stage of crystal formation, high concentrations of oxalate exposure may damage the renal tubular cells and cause oxidative stress after which the cells may be attached to the crystal thus supporting the oxalate-induced injury as the driving factor of crystal precipitation and cellular adhesion. However, at present, although various drugs targeting kidney stones have been proposed and evaluated both in vitro and in vivo , clinical drugs for stone dissolution have rarely been explored. Moreover, numerous advances in renal calcium oxalate stone associated target and drugs warrant their summarization until now, which could be further discussed and may provide potential ideas or options for exploration of renal calcium oxalate stone treatment targets and drugs. [ABSTRACT FROM AUTHOR]